Left Main Coronary Artery Stenosis and Angioplasty With Taxus Stent
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine whether percutaneous coronary angioplasty with Taxus drug eluting stent is safe and effective in the treatment of unprotected left main coronary artery disease associated to other coronary lesions or not.
Condition or disease
Device: Percutaneous coronary intervention with Taxus stent
Coronary artery bypass graft is the reference treatment of left main coronary artery disease. With the advancements of technology and particularly drug-eluting stents, in-stent restenosis has dramatically decreased and now it is possible to extend indications of complexes lesions such as left main coronary artery stenoses. In these particular situations,some centers performed percutaneous coronary angioplasty (PCI) with drug-eluting stents with acceptable results in terms of safety and efficacy. However, these procedures are performed at isolated sites and are not evaluated in multicenter trial.The aim of this study is to assess the safety and efficacy of this PCI with Taxus-stent in a french multicenter trial and to evaluate clinical and angiographic outcome of these patients at long-term follow-up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The patient must be > or = 18 years of age
Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee
Aspirin + Clopidogrel > or = 12 hours before percutaneous coronary intervention (PCI)
Documented evidence of ischemic heart disease (clinical,biological or ECG) with unprotected left main coronary artery stenosis > or = 50% associated to other coronary lesions or not responsible of stable or unstable coronary syndrome above 48 hours
The target reference vessel diameter must be > or = 2.5 mm
Unprotected left main coronary artery disease eligible by coronary stenting
Restenosis lesion in left main coronary artery
Known allergies to the following: aspirin, clopidogrel,ticlopidine,contrast agent or drug similar to paclitaxel
Acute coronary syndrome < 48 hours
Impaired renal function (creatinine > 180 ùmol/l) at the time of treatment
Life expectancy less than 36 months
Female of childbearing potential without reliable birth control
Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints